Previous close | 1,485.75 |
Open | 1,490.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 1,488.65 - 1,527.30 |
52-week range | 922.45 - 1,638.85 |
Volume | |
Avg. volume | 2,815,301 |
Market cap | 3.647T |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 40.93 |
EPS (TTM) | 37.14 |
Earnings date | 24 May 2024 - 28 May 2024 |
Forward dividend & yield | 12.50 (0.84%) |
Ex-dividend date | 09 Feb 2024 |
1y target est | 829.22 |
In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]
In this article, we will look into the top 20 most valuable Indian companies. If you want to skip our detailed analysis, you can go directly to the Top 5 Most Valuable Indian Companies. An Outlook of the Indian Economy According to Deloitte’s Indian Economic Outlook 2023, The Indian economy is poised to emerge as […]
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern